The statutory ban on Medicare paying for weight-loss drugs is still on the books. What changed on 1 July 2026 is that CMS opened a side door around it.
The Medicare GLP-1 Bridge is, in the agency’s own words, “a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.”[1] Beneficiaries who qualify pay a flat $50 copay for a weight-management GLP-1 — against a retail cash price that typically runs several hundred dollars a month.
The mechanism matters as much as the money
The Bridge does not expand Part D. It routes around it. CMS states the demonstration “will operate outside of the Medicare Part D benefit’s coverage and payment flow,” with the consequence that “Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge, and Part D sponsors do not have to opt in.”[1]
That last clause is the part most coverage misses. Your plan does not have to participate for you to be eligible, because your plan is not the payer. In 2026 CMS is using a single central processor to handle prior authorization, claims adjudication and pharmacy payment. It is also a Section 402 demonstration, not a Part D plan offering — a legal distinction that is exactly why it can exist alongside the coverage exclusion.
It was originally due to end sooner. CMS says the Bridge “will be extended through December 31, 2027” following the decision not to launch the BALANCE Model in 2027, using the extra time to “collect additional data on GLP-1 utilization to share with Part D plan sponsors.”[1]
Who qualifies
Eligibility is narrower than “on Medicare and want to lose weight.” A prescriber must submit a prior authorization attesting the patient is at least 18 and, at the time GLP-1 therapy was started, met one of three thresholds:[1]
- BMI ≥ 35, with no additional diagnosis required; or
- BMI ≥ 30 plus heart failure with preserved ejection fraction, uncontrolled hypertension (systolic above 140 mm Hg or diastolic above 90 mm Hg despite two antihypertensives), or chronic kidney disease stage 3a or above; or
- BMI ≥ 27 plus pre-diabetes per ADA guidelines, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease.
The timing clause is unusually generous and easy to miss. Criteria must be met at initiation, not at the moment of the request — explicitly including people who started before Medicare enrollment or before the Bridge existed. CMS’s own worked example: someone who began therapy in September 2024 at a BMI of 37 and is at 34 by a July 2026 request still qualifies, and the prescriber attests to the BMI at initiation.[1] In other words, succeeding on the drug does not disqualify you from continuing to afford it.
The exclusion that will surprise people
If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH, you are not eligible for the Bridge — even if you otherwise meet every criterion. Those indications are already covered under Part D, so CMS directs those beneficiaries back to their plan.[1]
This is a coverage rule, not a clinical one, and it produces a counterintuitive result: a sleep-apnea diagnosis can move you out of a $50 copay and back into your plan’s formulary tiering and prior-authorization process. The Bridge is reserved for people whose only qualifying indication is weight itself.
Plan types
Eligible: standalone prescription drug plans (PDPs) and Medicare Advantage coordinated care plans with drug coverage (MA-PD) — HMO, HMOPOS, and Local and Regional PPO — in CY 2026. Special Needs Plans, employer/union group waiver plans and the LI NET program are included, and dually-eligible beneficiaries in eligible plan types qualify.[1]
Not eligible: private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans and religious fraternal benefit plans — unless the beneficiary is also enrolled in a standalone PDP.[1]
What to do about it
The process starts with the prescriber, not the patient: the Bridge runs on prior authorization, and CMS operates a dedicated line for prescribers with questions about submitting or checking one — 855-273-0102, Monday to Friday, 8am to 7pm ET.[2] If you have been paying cash for compounded semaglutide or tirzepatide because Medicare would not cover the branded product, this is worth raising at your next appointment, particularly given the initiation-date rule.
One caveat worth stating plainly: this is a demonstration with an end date. Unless something replaces it, the $50 copay stops on 31 December 2027, and the underlying statutory exclusion is unchanged. Plan the medication decision around the clinical picture, not around a price that has a published expiry.